Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has issued an update.
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co has entered into agreements with China Merchants Bank to subscribe to structured deposit products totaling RMB100 million using its idle funds. These transactions are classified as discloseable under the Listing Rules, requiring reporting and announcement but not shareholder approval, potentially impacting the company’s financial management strategy.
More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co is a company operating in the biopharmaceutical industry, focusing on the development and commercialization of innovative pharmaceutical products. The company is involved in creating advanced medical solutions and has a market focus on leveraging its research capabilities to enhance healthcare outcomes.
Average Trading Volume: 18,256,511
Current Market Cap: HK$1.09B
For detailed information about 1349 stock, go to TipRanks’ Stock Analysis page.